AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01103570 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cholecystocholangiography
Description: a central venous pressure catheter was introduced through the anterior abdominal wall subcostally in a direction parallel to the gallbladder bed under direct vision so that it emerges close to the gall bladder. Then the catheter was advanced into the fundus of the gall bladder . The dye was prepared by diluting 20ml of 76% urografin with 20ml normal saline in a 50ml syringe
Study NCT01103570 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cystic duct cholangiography
Description: Then a 14G cannula was introduced through the anterior abdominal wall subcostally, (size 4F), was introduced through this cannula. The catheter was inserted into the cystic duct no more than 1 cm, by a grasper Then a 50ml syringe with the diluted urografin dye, as above, was attached to the catheter and cholangiography was performed by slowly injecting the dye under control of C-arm image intensifier.
Study NCT03935243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: equine assisted therapy
Description: The equine assisted group therapy is carried out by a riding therapist (nurse psychiatry HF, certified riding therapist SG-TR). There is a detailed plan for the PT.
Study NCT03935243 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: activating control phase
Description: The control phase includes a generally activating employment offer, such as board games, light physical activations, roundtables and artistic design.
Study NCT02176161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride Extended Release 750mg
Description: Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.
Study NCT02443168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221
Description: Part 1: oral solution containing 100 mg \[14C\]-AG-221
Study NCT02443168 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 14C AG-221
Description: 5 mL of 100 micrograms \[14C\] AG-221 given intravenously 4 hours after swallowing the formulated tablet.
Study NCT00766714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook K-SOFT-5100 catheter
Description: A Cook K-SOFT-5100 catheter was used for embryo transfer in human IVF/ICSI
Study NCT00766714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Frydman classical catheter
Description: A Frydman classical catheter was used for embryo transfer in human IVF/ICSI
Study NCT03933228 — intervention group
Intervention type: PROCEDURE
Intervention: Interscalene-Cervical Plexus Block
Description: Ultrasound-Guided Combined Interscalene-Cervical Plexus Block
Study NCT03933228 — intervention group
Intervention type: PROCEDURE
Intervention: Supraclavicular-Cervical Plexus Block
Description: Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block
Study NCT02932748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Portion Controlled Meals (PCM)
Description: Portion controlled meals provide conveniently packaged, low-energy, high-nutritional content food.
Study NCT02932748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Phone (GP)
Description: Weight management program delivered via group conference call.
Study NCT02932748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Diet
Description: Conventional diet (CD) will consist of a nutritionally balanced, reduced energy, high volume, lower fat (fat= 20-30% energy) diet based on USDA's MyPlate recommendations.
Study NCT02932748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Phone (IP)
Description: Weight management program delivered via individual phone call.
Study NCT02932748 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Weight management topics delivered face-to-face at clinic office every 6 months.
Study NCT00913939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Guided Needles to deliver HDR Brachytherapy
Description: Patients in this arm will receive two fractions (treatments) of brachytherapy over 14 days (+/- 7 days).
Study NCT00913939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Guided Needles to deliver HDR Brachytherapy
Description: Patients in this arm will receive 2 fractions (treatments) of brachytherapy before the start of RT, and 4-5 weeks towards the end of EBRT.
Study NCT00596830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871 (Figitumumab)
Description: CP 751,871 is a potent and selective fully human monoclonal antibody against the insulin like growth factor 1 receptor (IGF-1R). Patients in Arm A will receive CP-751, 871 intravenously every 21 days for up to six cycles.
Study NCT00596830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive carboplatin intravenously every 21 days for up to six cycles.
Study NCT00596830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive paclitaxel intravenously every 21 days for up to six cycles.
Study NCT00596830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive carboplatin intravenously every 21 days for up to six cycles.
Study NCT00596830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive paclitaxel intravenously every 21 days for up to six cycles.
Study NCT02056093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSV mode
Description: Application of PSV in all patients
Study NCT02056093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAV mode
Description: Application of PAV mode in all patients
Study NCT02056093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA
Study NCT03326206 — intervention group
Intervention type: OTHER
Intervention: COPE Program
Description: The COPE Program is a programmatic model that is designed to support to providers, Community Health Representatives, and patients/family members. Patients are referred to the COPE Program under program auspices. COPE referral and participation is part of routine care at all service units in Navajo Area Indian Health Services, and enrollment is not influenced by study participation. Patients receive the same health care services in the same manner and intensity, whether or not they are not enrolled in this observational study.
Study NCT04298957 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cone biopsy
Description: Cone biopsy if transformation Zone (TZ) 2 or TZ 3
Study NCT01539473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-controlled withTyramine
Description: Placebo-controlled and Tyramine
Study NCT01527292 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiation Therapy
Description: SRT only
Study NCT01527292 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRT with Vertebral Augmentation Procedure
Description: SRT with VAP
Study NCT03011359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimizing B.I (New) PCA mode
Description: In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: \~ 6 hr: 1.5 - 3.5 ml, 6-24 hr: 1 - 3 ml, 24 hr \~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 3.5 ml (or 0.5 ml).
Study NCT03011359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional PCA mode
Description: (Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes)
Study NCT03913091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Liposomal Bupivacaine Plus 0.5% Bupivacaine HCL
Study NCT03913091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Bupivacaine HCL
Description: 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB)
Study NCT00903812 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention as observational study
Study NCT02231346 — intervention group
Intervention type: DRUG
Intervention: Berodual® Respimat® - inhaler
Study NCT04289116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: We Test
Description: This design tests the added benefits of adjunct intervention components delivered prior to receipt of CHTC-Assertive Communication Training (ACT) videos viewed by the couple separately and individually delivered Motivational Interviewing-based Communication Skills Training (MI-CST). These target the development of communication skills necessary to participate fully in HIV prevention and sexual safety discussions inherent to CHTC.
Study NCT04289116 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IHTC
Description: Individual HIV Testing and Counseling
Study NCT02273219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Description: Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)
Study NCT03359811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthetic Solution
Description: A bolus or infusion of local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
Study NCT03359811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: 30 mg of Bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) injected before surgical incision in each of the four quadrants.
Study NCT03359811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: 65 mg of Liposomal Bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
Study NCT00790595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
Study NCT00790595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
Study NCT00790595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
Study NCT00790595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
Study NCT00790595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
Study NCT01994070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Electrical-first
Description: Patients will be placed on cardiopulmonary blood pressure monitoring, and sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient. If atrial fibrillation is maintained, the patient will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient, otherwise a cardiologist will be consulted.
Study NCT01994070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemical-first
Description: Patients will be placed on cardiopulmonary blood pressure monitoring, and will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient. If the rhythm has not changed, then the patient will be continue to have cardiopulmonary monitoring, but also be attended by a respiratory therapist. The patient will be sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient, otherwise a cardiologist will be consulted.
Study NCT01770080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Euminz®
Description: 3 to 5 time topical use of study drug.
Study NCT01770080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 to 5 time topical use of study drug.
Study NCT00884195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude Journaling
Description: Participants will be asked to write down 5 things every day for which they are grateful.
Study NCT00884195 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Journaling
Description: Participants will be asked to write down 5 things every day that they noticed about being involved in a weight loss program.
Study NCT04340102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BecomeAnEx
Description: This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
Study NCT05069909 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Denture Fabrication technique
Description: Each patient received two sets of dentures fabricated using the two different techniques and their satisfaction and OHIP-EDENT were compared
Study NCT01023360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel and proton pump inhibitors
Description: baseline detection --> clopidogrel 75 mg PO QD for 1 week --> clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week -->~1 week washout --> aspirin 100mg PO QD for 1 week
Study NCT04887519 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT01919801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema
Study NCT01919801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00248807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.25 mg enalaprilat IV
Description: an angiotensin converting enzyme (ACE) inhibitor given to lower blood pressure (BP) and measure cerebral blood flow (CBF)
Study NCT00248807 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Head up tilt (HUT)
Description: 45 degree head-up tilt to lower blood pressure and measure cerebral blood flow.
Study NCT00248807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Head up tilt (HUT)
Description: 45 degree head-up tilt to lower blood pressure and measure cerebral blood flow.
Study NCT02093156 — intervention group
Intervention type: OTHER
Intervention: Bowel preparation instructions
Description: The same-day preparation method was used as previously reported. Briefly, all patients were instructed to have a regular diet for breakfast and lunch, but only clear liquids for dinner on the day before the colonoscopy. They were asked to drink two bags of PEG-ELP (polyethylene glycol electrolyte powder) dissolved in 2 L of water, or 45 mL of sodium phosphate be diluted in 240 mL of cool water follow with at least 1.5 L of water at 05:00-06:00 h within 2 h on the day of colonoscopy. Patients were encouraged to drink more clear liquids after purgatives for adequate hydration before colonoscopy.
Study NCT01720901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib will be administered 250 mg one time by month, 3 times per day.
Study NCT02679560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine
Study NCT02679560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine HCL
Description: Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
Study NCT03937531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bladder Scanner
Description: PVR will be measured by using a bladder scanner.
Study NCT03937531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Scanner
Description: PVR will be measured by using a bladder scanner.
Study NCT01059994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sildenafil
Description: Oral, daily, 1 week.
Study NCT01059994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: oral, 25mg, daily for 1 week
Study NCT01090440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1144814
Description: This study is an open label, randomised, three-way cross-over study to evaluate the pharmacokinetics, effect of food, safety and tolerability of a new tablet formulation of GSK1144814 in healthy male and female (non-child bearing potential) subjects. Sixteen subjects will be enrolled to provide a minimum number of 12 evaluable subjects. The doses to be administered will be 100 mg and 200mg in the fasted state, and 100mg following a high fat breakfast.
Study NCT03637569 — intervention group
Intervention type: OTHER
Intervention: Measurement of triceps skinfold thickness
Description: By using skin thickness caliper, measure triceps skinfold thickness on the half of forearm (Rt side). In every 3 weeks, triceps skinfold thickness will be measured.
Study NCT01854502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hygiene and fluoride use
Description: Parents were given instructions how to brush and clean between teeth and to use fluoride toothpaste two times a day.
Study NCT00765570 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Spatially Fractioned Radiation Therapy
Description: evaluate response to radiation therapy by a large bulky tumor influenced by adding a single dose of 15 Gy grid radiotherapy.
Study NCT00765570 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Group 1
Description: one treatment of Grid therapy followed by 15 treatments with standard radiation
Study NCT00765570 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radiation
Description: 15 Standard radiation treatments
Study NCT00765570 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radiation
Description: standard radiation treatment
Study NCT01854502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and use of xylitol
Description: Parents were asked to fill in one-day diaries of their own diet in the waiting room. The dental professional pointed out the frequency of meals and snacks, as well as suggested the timing of xylitol products.
Study NCT05299060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cyanoacrylate adhesive (SecurePortIV®)
Description: Application of cyanoacrylate tissue adhesive (SecurePortIV®) to the puncture site plus standard wound care.
Study NCT01436474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
Study NCT05299060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard cure
Description: The standard cure consists of:~* Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops.~* Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV) and sutureless fixation device (BD-19940 StatLock™ PICC Plus).